The present disclosure is directed to fluorophosphates of formula (I), and pharmaceutical compositions thereof, which are inhibitors of intestinal apical sodium/phosphate co-transport and are useful in the treatment of hyperphosphatemia, in reducing blood phosphate levels, and in treating hypertension. Example of a compound of formula (I) is 2’-fluorophosphophloretin (2’-FPP).